NIH, Geom to conduct Phase I of GT-1

NIH's National Institute of Allergy and Infectious Diseases (NIAID) and Geom Therapeutics Inc. (San Diego, Calif.) partnered to conduct a Phase I trial of Geom's lead candidate GT-1 (LCB10-0200). The double-blind, placebo-controlled, dose-escalation study will evaluate safety and pharmacokinetics in healthy volunteers...